Business Context and Reporting Period
Company: Zimmer Holdings, Inc. (now Zimmer Biomet Holdings, Inc.)
Filing Date: April 24, 2014
Event: Entry into a Material Definitive Agreement (Merger Agreement) to acquire LVB Acquisition, Inc., the parent company of Biomet, Inc.
Key Financial Metrics and Transaction Terms
- Total Merger Consideration: Approximately $13.35 billion, comprised of $10.35 billion in cash and 32,704,677 shares of Zimmer common stock (valued at approximately $3.0 billion based on a $91.73 VWAP).
- Debt Assumption: Zimmer will pay off LVB's outstanding funded debt of approximately $5.7 billion. This amount is deducted from the cash consideration paid at closing.
- Financing Commitment: A commitment letter secured for a 364-day bridge term loan facility up to $7.66 billion and senior unsecured bank credit facilities up to $4.35 billion.
- Termination Fee: $800 million payable by Zimmer to LVB if the agreement is terminated due to failure to obtain required antitrust approvals.
Material Changes and Transaction Structure
Zimmer Holdings, Inc. entered into an Agreement and Plan of Merger with LVB Acquisition, Inc. and its subsidiary, Owl Merger Sub, Inc. The transaction involves the merger of Merger Sub with and into LVB, with LVB surviving as an indirect wholly owned subsidiary of Zimmer. The deal is not subject to a financing condition but requires customary closing conditions, including regulatory approvals (Hart-Scott Rodino and European Commission), SEC effectiveness of Form S-4, and LVB stockholder approval.
Guidance, Outlook, Risks, and Contingencies
- Timeline: The merger must be completed by April 24, 2015, extendable to July 23, 2015, if regulatory approvals are pending but other conditions are met.
- Marketing Period: Zimmer is not required to close until the completion of a 15 consecutive business day marketing period.
- Key Risks: Failure to obtain antitrust approvals, inability to realize anticipated synergies, integration challenges, disruption of management attention, and changes in healthcare reimbursement or regulatory environments (e.g., FDA, U.S. excise tax on medical devices).
- Forward-Looking Statements: Management expects benefits from the merger but notes significant uncertainties regarding timing, regulatory conditions, and operational integration.
Investor Verification Checklist
- Verify the status of antitrust regulatory approvals from the U.S. and European Commission.
- Confirm the effectiveness of the Form S-4 registration statement filed with the SEC.
- Monitor the outcome of the LVB stockholder vote on the Merger Agreement.
- Review the final terms of the financing commitment and any potential reductions due to interim debt or equity offerings.
- Assess the impact of the $5.7 billion debt payoff on the net cash outflow at closing.